Contineum Therapeutics, Inc. Class A Common Stock (CTNM) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 79K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | -79K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 16.9M | 17.11M | 14.93M | 17.82M | 18.11M | -84.74M | 12.97M | 10.94M | 9.93M | 9.68M | 8.07M | 5.12M | 5.45M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.26M | 4.36M | 3.94M | 3.84M | 4.4M | 4.03M | 3.25M | 3.04M | 2.15M | 1.66M | 1.57M | 1.48M | 1.5M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 11.65M | 12.76M | 10.99M | 13.98M | 13.71M | 13.02M | 9.73M | 7.9M | 7.78M | 8.01M | 6.5M | 3.63M | 3.95M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16.9M | -17.11M | -14.93M | -17.9M | -18.11M | 84.74M | -12.97M | -10.94M | -9.93M | -9.68M | -8.07M | -5.12M | -5.45M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 6.66% | -120.2% | -15.09% | -63.58% | -82.38% | 975.79% | -60.79% | - | -94.13% | -77.57% | - | - | - |
| EBITDA | -16.82M | -17.03M | -14.85M | -17.82M | -18.03M | 84.82M | -12.91M | -10.88M | -9.87M | -9.64M | -8.03M | -5.04M | -5.37M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 6.72% | -120.08% | -15.02% | -63.75% | -82.71% | 979.93% | -60.88% | - | -95.74% | -79.56% | - | - | - |
| D&A (Non-Cash Add-back) | 83K | 85K | 81K | 79K | 78K | 75K | 62K | 60K | 61K | 37K | 43K | 73K | 81K |
| EBIT | -16.9M | -17.11M | -14.93M | -16.04M | -18.11M | -14.56M | -10.27M | -9.01M | -9.93M | -7.93M | -6.37M | -4.73M | -7.41M |
| Net Interest Income | 2.5M | 2.01M | 1.96M | 2.03M | 2.25M | 2.53M | 2.74M | 2M | 1.64M | 1.79M | 1.74M | 309K | 241K |
| Interest Income | 2.5M | 2.01M | 1.96M | 2.03M | 2.25M | 2.53M | 2.74M | 2M | 1.64M | 1.79M | 1.74M | 401K | 342K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 92K | 101K |
| Other Income/Expense | 2.45M | 1.96M | 2.14M | 1.86M | 2.12M | -99.31M | 2.71M | 1.94M | 1.51M | 1.75M | 1.7M | 291K | -2.06M |
| Pretax Income | -14.46M | -15.16M | -12.79M | -16.04M | -15.99M | -14.56M | -10.27M | -9.01M | -8.42M | -7.93M | -6.37M | -4.82M | -7.51M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -161K | -118K | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2.03% | 1.85% | 0% | 0% |
| Net Income | -14.46M | -15.16M | -12.79M | -16.04M | -15.99M | -14.56M | -10.27M | -9.01M | -8.42M | -7.77M | -6.25M | -4.82M | -7.51M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 9.59% | -4.06% | -24.59% | -78.04% | -89.97% | -87.48% | -64.25% | - | -74.48% | -3.42% | - | - | - |
| Net Income (Continuing) | -14.46M | -15.16M | -12.79M | -16.04M | -15.99M | -14.56M | -10.27M | -9.01M | -8.42M | -7.77M | -6.25M | -4.82M | -7.51M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.39 | -0.49 | -0.45 | -0.62 | -0.62 | -0.56 | -0.40 | -0.35 | -0.33 | -0.05 | -0.25 | -0.19 | -0.30 |
| EPS Growth % | 37.1% | 12.5% | -12.5% | -77.14% | -87.88% | -1078.95% | -60% | - | -73.68% | 84.17% | - | - | - |
| EPS (Basic) | -0.39 | -0.49 | -0.45 | -0.62 | -0.62 | -0.56 | -0.40 | -0.35 | -0.33 | -0.05 | -0.25 | -0.19 | -0.30 |
| Diluted Shares Outstanding | 37.34M | 30.86M | 28.12M | 25.9M | 25.87M | 25.85M | 25.74M | 25.72M | 25.72M | 25.13M | 25.13M | 25.72M | 25.13M |
| Basic Shares Outstanding | 37.34M | 30.86M | 28.12M | 25.9M | 25.87M | 25.85M | 25.74M | 25.72M | 25.72M | 25.13M | 25.13M | 25.72M | 25.13M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - |